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ABSTRACT
Both preclinical and clinical investigations suggest that Notch signalling is critical 
for the development of many cancers and for their response to chemotherapy. We 
previously showed that Notch inhibition abrogates stromal-induced chemoresistance 
in lymphoid neoplasms. However, the role of Notch in acute myeloid leukemia (AML) 
and its contribution to the crosstalk between leukemia cells and bone marrow stromal 
cells remain controversial. Thus, we evaluated the role of the Notch pathway in the 
proliferation, survival and chemoresistance of AML cells in co-culture with bone 
marrow mesenchymal stromal cells expanded from both healthy donors (hBM-MSCs) 
and AML patients (hBM-MSCs*). As compared to hBM-MSCs, hBM-MSCs* showed 
higher level of Notch1, Jagged1 as well as the main Notch target gene HES1. Notably, 
hBM-MSCs* induced expression and activation of Notch signalling in AML cells, 
supporting AML proliferation and being more efficientin inducing AML chemoresistance 
than hBM-MSCs*. Pharmacological inhibition of Notch using combinations of Notch 
receptor-blocking antibodies or gamma-secretase inhibitors (GSIs), in presence of 
chemotherapeutic agents, significant lowered the supportive effect of hBM-MSCs and 
hBM-MSCs* towards AML cells, by activating apoptotic cascade and reducing protein 
level of STAT3, AKT and NF-κB.
These results suggest that Notch signalling inhibition, by overcoming the stromal-
mediated promotion of chemoresistance,may represent a potential therapeutic 
targetnot only for lymphoid neoplasms, but also for AML.
INTRODUCTION
Acute myeloid leukemia (AML) is the most 
common malignant myeloid disorder in adulthood, 
characterized by the blockage of myeloid differentiation 
and blast cell accumulation in the bone marrow [1]. One 
of the major challenges in AML, with the exception of 
promyelocytic acute leukemia, is still related to the high 
relapse rate after chemotherapy due to the persistence 
of residual blast cells in the bone marrow. In this 
phenomenon, stromal cell components of bone marrow 
niche, deriving from human mesenchymal stromal cells 
(hBM-MSCs), play a crucial role by supporting leukemia 
cell survival and growth, thus leading to escape from 
chemotherapy-induced apoptosis [2-5]. The crosstalk 
between leukemia cells and stromal microenvironment 
is complex and involves different pathways, including 
Wnt/β-catenin, Sonic Hedgehog and Notch. Notch is a 
developmental and evolutionary pathway that controls 
proliferation, self-renewal, differentiation and survival of 
normal and cancer cells. Notch signalling consists of four 
receptors, Notch1 to Notch4, and five ligands including 
Jagged1, Jagged2, Dll1, Dll3 and Dll4. The binding of 
the ligand to its cognate receptor induces the release of 
the Notch Intracellular Cleaved Domain (NICD) that, 
in turn,migrates into the nucleus. Then, in association 
with co-activators, such as C-promoter Binding Factor 1 
(CBF1) and Mastermind-like proteins (MAML), NICD 
trans-activates target genes, including Hairy and Enhancer 
of Split related gene-1 (HES-1). Depending on the cell 
system, Notch signalling may act as tumor suppressor or 
oncogene [6]. In hematological malignancies, activating 
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mutations of Notch1 are found in 50% of T-cell acute 
lymphoblastic leukemia (T-ALL) [7, 8]. Similarly, 
chronic lymphocytic leukemia (CLL) and B-cell acute 
lymphoblastic leukaemia cells (B-ALL) express Notch 
receptors and ligands and are sensitive to Notch signalling 
inhibitors [4, 5, 9, 10].
In myeloid counterpart the role of Notch remains 
controversial: some authors described Notch expression 
and activation in AML samples and AML cell lines, but 
the pathway was slightly activated, as demonstrated by 
the low expression level of Notch target genes [11-13]. 
Consistently, they demonstrated that the reactivation of 
Notch signalling induced apoptosis and differentiation 
of blast cells into mature cells [11, 12]. By contrast, the 
activation of Notch pathway in AML has been associated 
to bad prognosis[14]. Moreover, patients with hyper-
expression of Notch1 displayed poorer overall survival 
[15]. Recently, Grieselhuber and co-worker identified 
Notch expression and activation in acute promyelocytic 
leukemia, demonstrating that both genetic and 
pharmacologic inhibition of Notch signalling abrogated 
the enhanced self-renewal of blast cells [16]. However, the 
effect of exogenous micro-environmental Notch signalling 
on AML cell survival and response to chemotherapy has 
not yet been evaluated. 
In the present study, we demonstrate that hBM-
MSCs isolated from patients with AML (hBM-MSCs*) 
possess a different Notch expression pattern as compared 
to hBM-MSCs obtained from healthy donors. Moreover, 
hBM-MSCs* display more pronounced chemo-protective 
features. Using pharmacological inhibition of Notch 
pathway or specific blocking antibodies, we found that 
Notch blockade inhibits AML proliferation and abrogates 
hBM-MSC-mediated AML resistance to chemotherapeutic 
agents through the modulation of pro-/anti-apoptotic 
proteins balance and levels of prosurvival proteins, 
including AKT, STAT3 and NF-kB. Overall, these 
findings suggest for the first time that Notch signalling 
is important for chemo-resistance in the bone marrow 
microenvironment of AML patients, thus representing a 
potential target to improve AML treatment.
RESULTS
Notch signalling is expressed by hBM-MSCs from 
AML patients
To address a possible role for Notch signalling in 
the interaction between stromal microenvironment and 
leukemia cells, we first examined the expression of Notch 
pathway component in hBM-MSC from 12 healthy donors 
(hBM-MSC) and 12 AML patients (hBM-MSC*). hBM-
MSCs and hBM-MSC* were isolated through plastic 
adherence and characterized for mesenchymal markers 
expression (Figure 1A) and multilineage differentiation 
capacities (Figure 1B). Notch expression by hBM-MSCs 
and hBM-MSCs* was quantified through Western blot 
followed by densitometry analysis, by using Image 
J-software. Notch receptors are generally expressed in 
different forms including the Full-Length receptor (FL, 
200-280 kDa) and the Notch Trans-Membrane form 
(NTM, 90-110kDa).We found that hBM-MSCs and hBM-
MSCs* expressed all the four Notch receptors as well as 
the Notch ligand Jagged1 (Figure S1).Importantly, the 
mean level of Notch1 and Jagged1 proteins was higher 
in hBM-MSCs* than in hBM-MSCs (Figure 1C). By 
contrast, Notch3 was less represented in hBM-MSCs* 
as compared to hBM-MSCs, while the two cell types 
displayed the same level of NTM3. Accordingly, NTM3/
FL-Notch3 ratio was higher in hBM-MSCs* than in hBM-
MSCs. Differently from hBM-MSCs, which expressed 
low to undetectable levels of the Notch target gene Hes1, 
hBM-MSCs*showed higher level of Hes1 protein, thus 
suggesting that active Notch signalling is operational in 
bone marrow microenvironment of AML patients (Figure 
1C). 
hBM-MSCs modulate Notch expression in AML 
cells, supporting survival of primary AML cells
Overexpression and activation of Notch signalling 
in hBM-MSCs* from AML patients suggested a specific 
Notch signalling involvement in the bone marrow niche 
for the crosstalk between AML cells and stromal cells. 
A first attempt to validate this hypothesis was to analyse 
the expression of Notch components in AML cells 
isolated from peripheral blood (PB, n = 16) and from 
bone marrow (BM, n = 28). Globally, through FACS 
analysis (Figure S1C), we found a significant expression 
of Notch components in all the samples, with high levels 
of Notch1, Notch2, Jagged2 and Dll3 (Figure 2A). 
Regardless of the FAB and cytogenetic subtype, all BM 
samples showed higher levels of Notch1 and Notch2 as 
compared to PB samples (Figure 2B). To further validate 
this finding, we confirmed the higher levels of Notch1 and 
Notch2 expression in BM as compared to PB samples in 
a subset of 9 patients in which both BM and PB samples 
were available at diagnosis (Figure 2C). Noteworthy, 
the presence of Notch receptors on cell surface did not 
correlate with the signalling activation status. Indeed, 
only a subset of patients showed active Notch system, 
as revealed by the presence of Hes1, NICD1, NICD2 
and NICD3 (Figure 2D). Similarly, Western blot analysis 
showed the presence of NICD1, NICD2, NICD3 and 
Hes1 in some AML cell lines, namely HL-60 and THP1 
(Figure 2C, right). Notably, the expression of all these 
molecules was affected by the treatment with GSI (Figures 
S2A, S2B). In all the AML cell lines we also confirmed 
the presence, at variable levels, of Notch1 and Notch3 
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receptors, Jagged1, Jagged2 (only in THP1 cell line), 
Dll1, Dll3 and Dll4 ligands (data not shown). Overall, the 
presence of the active form of the receptors suggested that 
Notch activation was related to the three receptors, leading 
to multiple regulation levels of Notch activation, including 
compensation, synergism and antagonism. 
To establish whether the interaction between stromal 
cells and AML cells involves Notch pathway, we co-
cultured AML cells with hBM-MSCs*.After 24 hours, we 
performed the immunophenotyping of Notch receptors 
and ligands on AML cells, thus finding the increase of 
Notch1 level (Figure 3A). To assess whether this change in 
expression was correlated to Notch pathway activation, we 
investigated the change in the Notch target gene expression 
in AML cell lines upon co-culture with hBM-MSCs*. Co-
cultured AML cells showed the increase of Hes1 level as 
well as NICD1 (Figures 3B, S2B), which was abrogated 
after medium supplementation with GSIs (Figure S2B). 
Figure 1: Notch expression in bone marrow MSCs isolated from healthy donors (hBM-MSCs) and AML patients 
(hBM-MSC*). A. Flow cytometry analysis of MSCs for expression of hematopoetic, endothelial and mesenchymal markers. B. Oil Red 
O staining (upper panel) and Alizarin Red staining (lower panel) of mesenchymal cells grown during 21 days in adypocyte and osteogenic 
differentiation media, respectively. C. Relative quantification of protein expression after densitometry analysis of immunoblots. Protein 
expression levels were normalized to expression levels of GAPDH, data are expressed as the mean ± SEM of 12 patients and 12 healthy 
donors *p < 0.05, **p < 0.01. HEK-293 cell line was used as positive control. NTM: Notch Trans-Membrane domain; FL: Full Length; EC: 
Notch Extracellular Cleaved domain. As indicated in the datasheet, anti-Notch4 detected 3 different isoforms (a, b and c). 
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Consistently, THP1 cells transfected with RBP-Jk GFP 
reporter and seeded on hBM-MSCs* showed enhanced 
GFP signal when normalized with THP1 transfected with 
CMV-GFP plasmid (Figure 3C), and the increase in RBP-
Jk GFP activity was similar to that observed when cells 
were challenged with Notch receptors ligands (Figure 3C). 
Importantly, hBM-MSCs* as well as Notch ligands were 
capable to promote the survival of AML primary cells 
in co-culture or in culture, respectively, as shown by the 
reduction of Topro-3 positive cells after 4 days of culture 
(Figure 3D). These data indicate that the Notch pathway 
may represent a mechanism through which stromal 
microenvironment and leukemia cells reciprocally interact 
inside the bone marrow niche, eventually promoting AML 
cell survival.
Notch inhibition suppresses AML proliferation
Previous studies showed that artificial activation 
of Notch signalling in AML cells, through NICD over-
expression, decreased cell viability by inducing apoptosis 
[11, 12]; conversely, activation with recombinant ligands 
produces contrasting effects [13, 17, 18]. Here, we 
observed that only leukemia cells expressing Hes1 and at 
least one Notch receptor cleaved/active form, as expected, 
were sensitive to in vitro treatment with GSIs (Figure 
S3A). We found that viability of the cell lines (THP1, 
HL-60) and primary AML cells displaying active Notch 
signalling (Figure 2D) was reduced in a dose-dependent 
manner by using GSIs, as measured by MTT assay; by 
Figure 2: Notch expression and activation in AML cells. A. FACS analysis of AML cells (n = 43) using fluorochrome-conjugated 
antibodies specific for extracellular Notch receptors and ligands. B. A comparison of the expression level of each component was carried 
out between leukemia cells from peripheral blood (PB) and leukemia cells from bone marrow (BM) C. In a subset of 9 patients, Notch1 and 
Notch2 levels were quantified in PB and BM from the same patient, and Mann-Whitney test was used to analyze the differences between 
means (*p < 0.05). In A, B and C, data were represented as relative Mean of Fluorescence Intensity (MFI). C. Representative western blots 
analysis for Hes1 and activated form of Notch receptors (NICD1, NICD2, NICD3) in AML samples (left) and in cell lines (right). Data are 
representative of 4 independent experiments; HEK-293 and CEM cell lines were used as positive controls.
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contrast, hBM-MSCs and hBM-MSCs* viability was not 
affected by GSIs, except for higher concentration (Figure 
4A). However, we observed that the main effect of GSIs 
and SAHM1, a pharmacological inhibitor of MAML1, 
was related to the inhibition of cell proliferation more 
than induction of cell death (Table S3). To further confirm 
these observations, AML cells were stained with CFSE 
before GSI treatment (15µM for GSI-IX and 10µM for 
GSI-XII) to evaluate cell proliferation. GSI-treated AML 
cells showed high CFSE staining after 4 days of culture, 
as compared to DMSO (vehicle of GSIs)-treated cells, 
corresponding to GSI-induced inhibition of AML cell 
proliferation (Figure 4B). Consistently, the presence 
of Jagged1 slightly increased the proliferation of THP1 
and primary leukemia cells. To confirm the specificity of 
Notch modulators, each of them was used to treat THP1 
Figure 3: Modulation of Notch expression and activation in AML and hBM-MSCs* upon co-culture. A. Representative 
change in Notch1 level in AML cells: after 24 hours of co-culture with hBM-MSCs*, AML cells were collected and flow cytometry 
analysis for Notch1 expression was performed. The relative MFI was calculated and normalized as percentage with relative MFI of AML 
cells cultured alone. Data are expressed as mean ± SEM of 4 independent experiments. B. Representative western blot analysis of Hes1 
in AML cells after 24 hours of co-culture with hBM-MSCs*. C. Representative RBP-jk activity in THP1 cells expressing RBP-jk-GFP 
reporter gene, THP1 cells were transfected with RBP-jk GFP reporter gene, after 4 hours cells were treated with Notch ligands or seeded 
on hBM-MSCs* monolayer. GFP levels were analyzed through flow cytometry after 72hours of co-culture. Data were normalized in 
percentage with THP1 transfected with CMV-GFP plasmid and are expressed as mean ± SEM of 4 independent experiments. D. Viability of 
primary leukemia cells cultured in presence of Notch ligands (Jagged1, Jagged2) or co-cultured with hBM-MSCs*. After 4 days, cells were 
collected and stained with Topro-3 to discriminate death cells through flow cytometry analysis. Data are representative of mean ± SEM of 
3-7 independent experiments involving 3-10 patients.
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transfected with RBP-Jk-GFP reporter plasmid. As above 
mantioned, the addition of ligands increased GFP signal, 
while inhibitors had the opposite effect (Figures 3C, S2C).
We then investigated the effect of stromal cells 
on AML cell proliferation. We found that hBM-MSCs 
inhibited AML cell proliferation, while hBM-MSCs* 
supported the proliferation of THP1 and primary 
leukemia cells (Figure 4C).The addition of GSIs to co-
culture reverted the supportive effect of hBM-MSCs* 
and increased the suppressive properties of hBM-MSCs 
towards AML cell proliferation (Figure 4D). Likewise, 
pan-inhibition of Notch using the Notch transcription 
factor inhibitor SAHM1, reduced AML cell proliferation 
without any effect on cell death (Figure S3 and Table S3).
AML cell lines silenced for RBP-jk are more 
sensible to chemotherapy
As hBM-MSC-mediated Notch signalling was 
involved in survival and proliferation of AML cells, we 
hypothesized that this contribution could be extended 
to AML response to chemotherapy. To validate this 
hypothesis, we decided to take advantage of a loss of 
function model of AML cells by silencing Notch in cells 
with active Notch pathways. As recombination signal-
binding protein Jκ (RBP-jk) is a key transcription factor 
downstream of receptor activation in Notch signalling 
pathway, its down-regulation by using short interfering 
RNA is largely used to mimic pan-Notch inhibition in 
different cancer cells systems (19,20). We therefore 
proceed to knocked-down RBP-jk in two AML cell 
lines displaying active Notch signalling, namely HL-
60 and THP1 (Figure 2D). Infection of these cell lines 
with shRBP-jk effectively inhibited RBP-jk in HL-60 
and THP1 (Figure 5A). We found that silenced cells 
were more sensible to treatment with Idarubucine than 
their counterpart infected with a non-specific shRNA 
(Figure 5B). This observation suggested that activation 
of Notch in AML by stromal microenvironment promotes 
chemoresistance.
Notch/GSI-inhibition abrogates drug resistance 
induced by stromal cells
We and other groups have previously demonstrated 
that bone marrow-derived stromal cells could protect 
leukemia cells from chemotherapy-induced apoptosis 
(2,4,5,21). To understand whether hBM-MSCs* could 
promote chemoresistance, we treated AML cells with 
drugs routinely used for AML therapy, i.e. Ara-C, 
Figure 4: Notch signalling controls AML cell proliferation in culture and in co-culture with hBM-MSCs*. A. AML 
cells were cultured with increasing concentrations of GSI-IX or GSI-XII for 48 hours,then cell viabilitywas analyzed through MTT assay. 
B. In order to quantify cell proliferation, CFSE-stained AML cells were cultured for 4 days in the presence of Notch modulators. Data 
are normalized by comparing each condition with untreated or DMSO treated wells. C. Effects of hBM-MSC and hBM-MSC* on the 
proliferation of AML cells in absence of Notch modulators. Data are compared with the proliferation of AML cultured alone or with DMSO 
that was normalized to 100% of cell proliferation. D. Effects of GSIs on AML cell proliferation in co-culture with hBM-MSCs*. Data are 
compared with AML/hBM-MSCs* culture condition, which was normalized to 100% of cell proliferation. Data are expressed as the mean 
± SEM of 5-10 independent experiments involving 10 patients: *p < 0.05, **p < 0.01, **p < 0.001.
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Figure 5: Drug sensibility of AML cell lines with RBP-jK knock down. A. Notch transcription factor regulator RBP-jk was 
silenced in AML cell lines HL-60 and THP1 using lentiviral particles expressing shRNA directed to RBP-jk. Knock down cells were treated 
with Idarubucin, in presence or absence of hBM-MSCs*. After 48 hours of treatment, AML cells were harvested and stained with PI to 
analyse cell viability. Data are expressed as mean ± SEM of three independent experiments:* p < 0.05
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Figure 6: hBM-MSCs* promote AML chemo-resistance. A. AML cells were cultured with increasing concentrations of 
chemotherapeutic agents (Ara-C, Etoposide and Idarubicine). After 48 hours, cell viability was analyzed with MTT assay to identify the 
EC50. Graphs are representative of 4 independent experiments. B. Cell lines and primary AML cells were treated with Ara-C, Etoposide or 
Idarubicin in presence or absence of hBM-MSCs*, and then stained with AnnexinV/PI in order to evaluate cell apoptosis. C. Cell lines and 
primary AML cells were treated with Idarubicin in presence or absence of hBM-MSCs or hBM-MSCs* and then stained with AnnexinV/
PI and analysed through flow cytometry. Data are expressed as the mean ± SEM of 5-10 independent experiments involving 10 patients: 
*p < 0.05, **p < 0.01, **p < 0.001
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Idarubicin and Etoposide. After 48 hours of treatment, cell 
viability was analyzed by MTT assay. As expected, drug 
treatment reduced AML cell survival in a dose-dependent 
manner (Figure 6A). We next confirmed that stromal cells 
support AML cell survival by preventing drug-induced 
apoptosis (Figure 6B). Notably, hBM-MSCs* displayed a 
stronger protective activity towards AML cells in presence 
of Idarubicin, as compared to hBM-MSCs (Figure 6C).
As GSI-IX, GSI-XII, SAHM1 and blocking 
antibodies were capable of reverting hBM-MSCs*-
dependent Notch activation in AML cells (Figure 7A), we 
therefore analyzed the viability, upon Notch inhibition, 
of drug-treated AML cells in co-culture with hBM-
MSCs*. We found that GSIs treatment increased the 
chemosensitivity of both cell lines and primary AML 
towards Idarubicin treatment (Figure 7B, 7C and Table 
S4). The same effect was obtained when leukemia cells 
were treated with Ara-C or Etoposide (Table S4) and in 
cell contact-independent setting by using Transwell® 
system (Figure S4). Although GSIs are good Notch 
inhibitors, they still have secondary targets, such as 
proteasome (22), thus displaying potential toxicity that 
may limit their clinical application. Thus, we confirmed 
that GSI and Idarubicin treatment did not affect hBM-
MSCs* viability and morphology (Figures S5A and S5B). 
Alternatively, the use of blocking antibodies is a current 
strategy for the treatment of many types of cancers 
[19]. Hence, we tested whether anti-Notch blocking 
antibodies were capable of abrogating hBM-MSC*-
mediated chemoresistance of AML cells. The addition of 
a mixture of anti-Notch1, anti-Notch2, anti-Notch3 and 
anti-Notch4 (pan-R-abs) or specific Anti-Notch blocking 
antibodies alone, significantly enhanced drug sensitivity 
of AML cells in co-culture with hBM-MSC* (Figures 
7C, S6). The addition of SAHM1 reverted only partially 
the chemoresistance, thus suggesting a role for MAML1-
independent Notch signalling activation in the stroma and 
AML crosstalk (Figure 7C).
Notch inhibition is associated with the activation 
of apoptotic cascade and decrease of prosurvival 
proteins, such asAKT, STAT3and NF-κB
It has been previously shown that bone marrow 
stromal cells prevent apoptosis of AML cells through 
Figure 7: Notch inhibitors abrogate hBM-MSC*-induced chemoresistance. A. THP1 cells were transfected with RBP-Jk 
GFP reporter gene; prior to transfection, cells were treated with Notch modulators, which were maintained in the medium during and after 
transfection. After 4 hours from transfection, cells were seeded on hBM-MSCs* monolayer. GFP levels were analyzed by flow cytometry 
after 72 hours of co-culture. Data were normalized in percentage with THP1 transfected with CMV-GFP plasmid and are expressed as mean 
± SEM of 2 independent experiments. B. AML cell lines were cultured alone or co-cultured with hBM-MSCs* in presence of Idarubicin 
(0.5 µM) and with increasing concentrations of GSIs. C. Primary AML cells were cultured alone or co-cultured with hBM-MSCs* in 
presence of Idarubicin (0.5 µM) and either increasing concentrations of GSIs or Notch transcription factor inhibitor SAHM1 (20µM) or a 
combination of anti-Notch1, 2, 3 and 4 blocking antibodies (pan-R-abs, pan Receptor blocking antibodies). All blocking antibodies were 
used at a final concentration of 5µg/ml. After 48 hours of treatment, AML cells were harvested and stained with AnnexinV/PI to analyze 
cell viability. Data are represented as mean ± SEM of 3 independent experiments. One way ANOVA was used for statistical analysis: * p < 
0.05, **p < 0.01, ***p < 0.001. “ve”: vehicle = DMSO.
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upregulation of anti-apoptotic proteins [21, 24]. We 
then assessed whether Notch inhibition influenced Bcl-2 
family proteins. We found that hBM-MSCs* co-culture 
led to the decrease of pro-apototic Bax / anti-apoptotic 
Bcl-2 ratio (Figure 8A) and the level of full-length 
caspase3 expression (Figure 8B). By contrast, GSIs were 
capable of increasing this ratio and reducing the level 
of full-length caspase3. These observations suggested 
that Notch inhibition could revert hBM-MSCs-mediated 
AML chemoresistance by modulating the balance 
between pro-apoptotic and anti-apoptotic of the Bcl-2 
family protein and the level of full-length caspase3. In 
parallel, we observed that cell lines with lower level of 
RBP-jk displayed reduced levels of AKT, STAT3 and NF-
kB expression (Figure 8C). Interestingly, these proteins 
have been linked to poor prognosis and represent good 
targets to overcome drug resistance [20-22]. We therefore 
investigated, upon pharmacological inhibition of Notch, 
the activation and expression levels of AKT, STAT3 
and NF-kB proteins. Activation status was screened 
through Western blot analysis of phospho-AKT (Thr308), 
phospho-STAT3(Tyr705), and phospho-NF-κB (Ser536) 
Figure 8: Notch inhibition controls Bax/Bcl-2 ratio and protein levels of Akt, NF-kB and Stat3. AML cells were cultured 
alone or co-cultured with hBM-MSCs* in presence of Idarubicin (0.5 µM) and either GSI-IX (20µM) or GSI-XII(15µM). A. After 24 hours 
of incubation, cells were collected washed, fixed, permeabilized, stained with anti-Bax-Alexa Fluor 488 and anti-Bcl-2-Alexa Fluor 488, 
and then analyzed through flow cytometry. Data are expressed as mean ± SEM of 3 independent experiments: *p < 0.05, **p < 0.01, ***p < 
0.001. B. Western blot analysis of Caspase3. C. Relative levels of AKT, NF-kB and STAT3 in shRBP-jk cells, cells in culture were washed, 
fixed, permeabilized and probed with corresponding primary antibody, followed by staining with PE-conjugated secondary antibody. Cells 
were then analysed through flow cytometry. Data are expressed as mean ± SEM of 3 independent experiment experiments *p < 0.05, **p 
< 0.01. D. Western blot analysis of Caspase3 AKT, STAT3, NF-κB. Data are representative of 3-4 patients.
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expression. However, the pattern of phosphorylation was 
not homogeneous among cell lines and AML cells, thus 
revealing a variable degree of activation of these pathways 
in hBM-MSC*-mediated AML chemoresistance (data not 
shown). By contrast, Idarubicin treatment reduced the 
level of NF-κB, STAT3 and AKT expression in AML cells 
after 24 hours of treatment. This decrease was partially 
abrogated when AML cells were co-cultured on hBM-
MSCs*, and the presence of GSIs in co-culture medium 
restored Idarubicin-dependent reduction of AKT, NF-κB 
and STAT3 proteins (Figure 8D).
DISCUSSION
Many of the most recent therapeutic approaches 
have shifted from targeting cancer cells to interfering with 
the microenvironment, as the influence on tumor cells of 
tissue microenvironment has been clearly shown to play a 
pivotal role in cancer cell chemoresistance and treatment 
failure [23]. In hematological malignancies, the presence 
of stromal cells promotes leukemic cell escape from 
apoptosis induced by chemotherapy(2,5,21), and leukemia 
development is often associated to persistent abnormalities 
in the microenvironment fostering neoplastic cell growth 
[24]. Amongst them, Wnt/β-catenin, Sonic Hedgehog 
and Notch pathways play an important role by regulating 
the crosstalk between leukemia cells and stromal 
microenvironment [25]. For instance, some activating 
mutations of β-catenin in osteoblast compartment are 
sufficient to generate AML-like disease in mouse model 
[26]. Interestingly, the accumulation of nuclear β-catenin 
induces Jagged1 expression in stromal cells, and the 
genetic or pharmacological inhibition of Notch signalling 
ameliorates the symptoms in mice, thus indicating the 
pathogenic role of Notch in AML [26]. In line with these 
observations, we demonstrate here that hBM-MSCs* 
show higher level of Jagged1 and Notch1 as compared to 
hBM-MSCs. In parallel, we observed that hBM-MSCs* 
failed to inhibit AML proliferation and were more potent 
than hBM-MSCs in mediating AML chemoresistance. In 
agreement with previous studies [12, 27], our data show 
that Notch was expressed by AML samples and MSCs 
from both normal donors and patients, thus indicating the 
possibility of crosstalk between the two cell types through 
this developmental pathway. This hypothesis is clearly 
supported by the observation that bone marrow leukemia 
cells expressed higher levels of Notch1 and Notch2 than 
peripheral blood-derived leukemia cells, thus suggesting 
that the interaction of leukemia cells with bone marrow 
stromal cells actively involves the Notch pathway. 
Previous studies described the poor activation 
of Notch in AML samples [11, 12, 28]. Nevertheless, 
accumulating evidence highlighted the role of Notch in the 
interaction between bone marrow microenvironment and 
leukemia cells by showing that hBM-MSCs are capable of 
inducing activation of Notch signalling in different cancer 
cells, including multiple myeloma, CLL, and T-ALL [4, 
5, 29, 30]. Regardless of FAB classification and genetic 
abnormalities, we found that 50% of AML cells expressed 
the activated form of Notch receptors, which were up-
regulated following the co-culture with either hBM-MSCs 
or hBM-MSCs*. Notably, Hes1-negative AML cells were 
induced to express Hes1 de novo following co-culture 
with hBM-MSCs. Putting these observations together, 
we hypothesized that Notch could be more expressed 
and activated in bone marrow, and such activation 
could be critical to mediate AML chemoresistance. 
Indeed, the inhibition of hBM-MSC-dependent Notch 
activation in Jurkat or myeloma cells sensitized the latter 
to chemotherapy [29, 30]. Accordingly, abrogation of 
chemoresistance was achieved when pan-Notch inhibitors, 
such as GSI-IX, GSI-XII, blocking antibody combination 
or SAHM1, were added to the co-culture. Consequently, 
we proposed a role for Notch inhibition in preventing 
hBM-MSCs*-induced chemoresistance of AML cells, 
and we tried to understand the molecular mechanisms 
involved. Apoptosis is a cascade of biochemical 
reactions involving activation of pro-apoptotic proteins 
of Bcl-2 family leading to activation of caspases, which 
are effectors of apoptosis. In AML, Bcl-2 inhibition 
induces apoptosis in a Bak/Bax-dependent manner, thus 
overcoming intrinsic and microenvironment-induced 
drug resistance [31]. We show here that Notch inhibition 
through GSIs substantially enhances Bax/Bcl-2 ratio;in 
parallel, we found that GSIs were also capable of 
decreasing the levels of full-length caspase3. These data 
suggest that the activation of Bax/caspase3 axis could be 
the consequence of Notch inhibition leading to prevention 
of hBM-MSCs*-mediated drug resistance. In addition, 
genetic or pharmacological inhibition of Notch was 
associated with the decrease of AKT, NF-κB and STAT3 
proteins, which all control proliferation and/or cell death, 
and are targets of caspases [32-34]. In particular, mTor/
AKT pathway is constitutively activated in 50-70% of 
AML cases, and mTor inhibitors, such as Rapamycin and 
Everolimus [35], have been proved effective, although 
highly toxic [32], in patients with relapsed/refractory 
AML. We observed that both pharmacological and genetic 
inhibition of Notch signalling is associated with decrease 
of AKT levels, making Notch inhibition an attractive 
alternative to target AKT/mTor axis. Thus, Notch 
inhibition could be achieved through many strategies 
including GSIs, SAHM1 and Notch blocking antibodies.
Blocking antibodies, such as Trastuzumab, 
Bevacizumab and many others, have shown to be highly 
effective as anti-cancer therapy [19]. They represent also 
a useful tool to experimentally investigate the role of 
specific receptors, by blocking their activation. In order 
to investigate the contribution of each Notch receptors 
in the crosstalk between AML cells and hBM-MSCs*, 
we added specific blocking antibodies to the co-culture. 
We found that Notch1 and Jagged1 blockade abrogated 
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hBM-MSCs*-mediated AML chemoresistance. Other 
studies have described the involvement of Notch1 and 
Jagged1 in microenvironment-mediated chemoresistance: 
indeed, the inhibition of Notch1 up-regulation in multiple 
myeloma is sufficient to abrogate hBM-MSC-induced 
chemoresistance [30]. Similarly, Jagged1 genetically 
silenced in tumor cells or tumor microenvironment leads 
to the reduction of AML symptoms and sensitizes tumor 
cells in ovarian cancer [26, 29]. However, in our co-
culture system, the chemoresistance abrogation mediated 
by the addition of anti-Notch1 and anti-Jagged1 was 
only partial, thus giving the cue for a possible role of 
other Notch components in this phenomenon. We have 
previously shown that Notch receptors involved in stromal 
cell-mediated chemoresistance were Notch1, Notch2 and 
Notch4 for CLL, and Notch3 and Notch 4 for B-ALL [4, 
5]. Here, we found in AML that the blockage of Notch2 
and Jagged2 was also capable of partially restoring the 
chemosensitivity, while Notch4 and Dll3 blockade 
abrogated totally AML chemoresistance.
In conclusion, our observation that Notch signalling 
plays a crucial role in AML cell survival mediated by bone 
marrow stromal cells may represent the biological basis 
for new treatment strategies that may become clinically 
relevant for AML eradication. In fact, the role of Notch 
pathway has been already described in other malignancies, 
such as acute lymphoblastic leukemia, and this finding 
has made a number of Notch pharmacological modulators 
available for clinical trials. Considering that non-
promyelocytic AML is the most frequent acute leukemia 
in adults, still without definitively curative approaches 
for most patients lacking bone marrow transplantation 
chance, the availability of specific inhibitors affecting 
stromal support to AML cells inside bone marrow could 
represent an important tool to improve the prognosis of 
AML patients. 
MATERIALS AND METHODS
Chemicals and antibodies
The antibodies used for FACS analysis were: mouse 
IgG2b-FITC, goat IgG-PE, anti-Jagged1-FITC, anti-Dll3-
PE (all from R&D System, Minneapolis, MN), mouse 
IgG2a-PE, mouse IgG1κ-PE, mouse IgG1-Alexa Fluor 
488,anti-Notch1-PE, anti-Notch2-PE, anti-Notch3-PE, 
anti-Notch4-PE, anti-Dll1-PE, anti-Dll4, anti-Bax-Alexa 
Fluor 488 (all from Biolegend, San Diego, CA) and rabbit 
anti-Bcl-2-FITC (DAKO). For leukemia cell identification 
we used anti-CD45-VioBlue, anti-CD45-APC-Vio770, 
anti-CD34-PerCP and anti-CD117-APC (all from 
MiltenyiBiotec, Germany).The antibodies employed for 
western blot analysis anti-Notch2, anti-Notch4 were from 
Santa Cruz (Biotechnology, Dallas, TX), anti-GAPDH 
and HRP conjugated secondary antibodies against mouse, 
rabbit or goat were from Sigma Aldrich. All the other 
antibodies used for Western blot were from Cell Signalling. 
Neutralizing antibodies,all used at a final concentration of 
5 μg/ml, were: anti-Notch1, anti-Notch3,anti-Jagged1, 
anti-Jagged2, anti-Dll1 and anti-Dll4 (R&D Systems); 
anti-Notch-4 (Santa Cruz Biotechnology); anti-Dll3 (CST, 
Boston, MA). Recombinant human Jagged-1 and Jagged-2 
were from R&D System. GSI-IX (DAPT) was purchased 
from Stemgent (Cambridge, MA) GSI-XII and SAHM1 
were from Merck Millipore (Darmstadt, Germany). 
Cytarabine (Ara-C), Etoposide (Eto) and Idarubicin 
(Ida) were provided by Pharmacy Unit of the University 
Hospital of Verona.
Patients, samples and cell lines
All cell samples were collected from newly 
diagnosed AML patients and healthy donors after written 
informed consent, as approved by the Ethical Committee 
of AziendaOspedalieraUniversitariaIntegrata Verona (N. 
Prog. 1828, May 12, 2010 - ‘Institution of cell and tissue 
collection for biomedical research in Onco-Hematology’). 
In detail, AML cells were obtained from bone marrow (n = 
28) or peripheral blood samples (n = 16) of patients with 
AML at diagnosis ( > 90% of leukemic cells) (Table S1A). 
Human BM-MSCs were obtained from 12 healthy donors 
and 12 AML patients (Table S1B). They were expanded in 
complete MEM-α (MEM-α supplemented with 10% fetal 
bovine serum (FBS), 1% L-Glutamine and 1% penicillin/
streptomycin). 
Human AML cell lines (HL-60, THP1, U937), CML 
cell line (K562), and T-ALL cell line (CEM) were cultured 
in complete RPMI (RPMI supplemented with 10%FBS, 
1% L-Glutamine and 1% Penicillin/Streptomycin). HEK-
293 were maintained in DMEM supplemented with 10% 
FBS, 1% L-Glutamine and 1% Penicillin/Streptomycin. 
Cell lines were validated for STR prior being purchased 
and were routinely verified to be Mycoplasm-free. 
Cell cultures and co-cultures
BM-MSCs were expanded and characterized as 
previously described[4, 5]. Co-culture experiments were 
performed in complete RPMI on a confluent monolayer 
of hBM-MSCs or hBM-MSCs* in 96-well plates: 105 
AML cells or 2 x 104cells from AML cell lines were 
seeded alone or on stromal monolayer supplemented 
with Notch modulators or different drugs used in AML 
treatment, including Cytarabine (Ara-C), Etoposide 
(Eto), Idarubicin (Ida). To determine EC50 dose for 
each drug and modulator, we performed the colorimetric 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide (MTT, Sigma-Aldrich) metabolic activity assay. 
Apoptosis was evaluated by AnnexinV-FITC assay 
Oncotarget21725www.impactjournals.com/oncotarget
(MiltenyiBiotec). To study cell proliferation, AML cells 
were labelled with carboxyfluoresceinsuccinimidylester 
(CFSE) (Life Technologies) (5mM). For primary leukemia 
cells proliferation assay, complete RPMI medium was 
supplemented with IL-3, IL-6 and SCF, as previously 
described (15). After 4 days, AML cells were harvested, 
stained with anti-CD45 PerCP-Vio700 antibody and 
analyzed by FACS CantoII (BD Biosciences). MTT, 
AnnexinV-FITC and CFSE assay are described in detailed 
in Supplementary Methods. 
Gene reporter assay
THP1 cells were transfected with reporter 
plasmids encoding for an inducible RBP-Jk-responsive 
GFP reporter (Qiagen) using MACSfectin transfection 
reagent (MiltenyiBiotec). GFP signal were quantitatively 
measured by flow cytometry. Notch activity was 
determined by normalizing the activity of RBP-Jk-GFP to 
that of CMV-GFP plasmid.
Generation of RBP-jk knockdown cell lines
The pLKO.1-puro-CMV-TurboGFP lentivirus 
plasmid (SHC003) was obtained from Sigma. For 
gene silencing, shRNA plasmids targeted to RBP-
jk, TRCN0000016207 (shRBP-jk), Scramble shRNA 
SHC016 were purchased from Sigma, as well asLentiviral 
Packaging Mix (SHP001). Plasmids were co-transfected 
into 293T cells usingMACSfectin transfection 
reagent (MiltenyiBiotec), at a ratio of 1:1(plasmid of 
shRNA:Packaging Mix). Media were replaced with 
DMEM + 10% FBS at 16 hours after transfection; viruses 
were collected at 48 and 72 hours after transfection and 
filtered through a 0.45 μm filter. HL-60 cells and THP1 
cells were transduced by the lentivirus in the presence of 
the polycation Polybrene, and the stably transduced cells 
were then selected by puromycin (1μg/ml) for 4 weeks.
Adipogenic and osteogenic differentiation
hBM-MSCs or hBM-MSCs* were seeded in 24 
wells plates. Once reached the confluence, cells were 
induced to differentiate by replacing growth medium by 
adipogenic or osteogenic differentiation media. Adipogenic 
differentiation medium consisted in DMEM supplemented 
with 18% FBS, 10mg/ml IBMX (Sigma-Aldrich), 
100U/ml Insulin (Lilly) and 1mM Dexamethasone 
(Sigma-Aldrich). For Osteogenic differentiation, cells 
were incubated with StemMACSOsteo Diff Medium 
(MiltenyiBiotec). Differentiation media were changed 
each 3 days and cells were allowed to differentiate for 
3 weeks; then cells were characterized with Oil Red O 
staining and Alizarin red for adipogenic andosteogenic 
differentiation, respectively.
Western blotting
Cells were lysed with an appropriate amount of 
RIPA buffer (25 nMTris pH 7.6, 150mM NaCl, 1% NP40, 
1% Na-deoxycholate, 0.1% SDS) supplemented with 
complete Protease Inhibitor (Roche) and 1 mM Na3VO4. 
Proteins were quantified using BCA protein assay kit 
(Thermo Scientific, Waltham, MA) and separated on a 
10% or 12% polyacrylamide gel. Subsequently, proteins 
were transferred onto nitrocellulose membrane (GE 
Healthcare), labelled with appropriate antibody and 
acquired by LAS4000 (GE Healthcare) instrument. 
Densitometric analyses were performed on scanned 
immunoblot images using the ImageJ analysis tool 
(National Institutes of Health, Bethesda, Maryland). 
GAPDH density was used to normalize density of each 
protein.
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism software (La Jolla, CA). Data were expressed as 
mean ± standard error means (SEM). Student t-test was 
used to compare 2 groups and one-way ANOVA followed 
by the Tukey’s range test were applied to compare multiple 
groups. Mann-Whittney test was used for non-coupled, 
non-parametric comparison.
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